pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition. C acnes is implicated in moderate to severe acne, which is difficult to treat.

Vaccination 105

Vaccination Vaccine Development Hormones 105

Pharmaceutical Technology

MAY 31, 2023

The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 5, 2024

Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. mg implant) is around $1,006.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. mg implant) is around $1,006.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

MAY 4, 2021

In February 2021, Pfizer and BioNTech announced results from an in vitro study published in NEJM that demonstrated sera from individuals immunized with BNT162b2 neutralize SARS-CoV-2 with the South African variant spike protein. The study investigated the full set of South African variant (also known as B.1.351

Vaccination 40

Vaccination Vaccine Production Sales 40